Abbott confirmed a $21 billion deal to acquire Exact Sciences, instantly becoming one of the biggest moves in diagnostics in years. Abbott will pay $105 per share in cash, a 51% premium, sending Exact’s stock sharply higher for a second straight day.
The deal gives Abbott a dominant foothold in cancer screening, powered by Exact’s flagship Cologuard test and a crowded pipeline of next-generation screening tools, including Cologuard Plus and several liquid-biopsy programs. CEO Robert Ford emphasized growth over cost-cutting, though analysts see room for efficiencies in sales infrastructure and procurement.
Exact’s footprint — 6,500 employees, nine R&D centers, and more than 20 million Cologuard tests used since 2014 — positions Abbott to scale quickly across primary care, where both companies already have deep commercial reach. But the combo isn’t plug-and-play: the two companies have different operating models, and Ford downplayed expectations of broad cross-selling between Cologuard and products like Libre.
The acquisition continues a surge in health-care M&A and could spark a new wave of consolidation across diagnostics. With the deal slated to close in mid-2026, investors will be watching how Abbott integrates Exact’s sprawling cancer-screening pipeline — and whether the company can convert this massive swing into long-term market leadership.